MX2020001434A - Analogos de insulina acilados novedosos y usos de estos. - Google Patents

Analogos de insulina acilados novedosos y usos de estos.

Info

Publication number
MX2020001434A
MX2020001434A MX2020001434A MX2020001434A MX2020001434A MX 2020001434 A MX2020001434 A MX 2020001434A MX 2020001434 A MX2020001434 A MX 2020001434A MX 2020001434 A MX2020001434 A MX 2020001434A MX 2020001434 A MX2020001434 A MX 2020001434A
Authority
MX
Mexico
Prior art keywords
insulin analogues
acylated insulin
novel acylated
novel
analogues
Prior art date
Application number
MX2020001434A
Other languages
English (en)
Inventor
Schäffer Lauge
Pettersson Ingrid
Skytte Olsen Grith
Falck Hansen Bo
Slaaby Rita
Brandt Jakob
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2020001434A publication Critical patent/MX2020001434A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation

Abstract

La presente invención se refiere a análogos de insulina novedosos y derivados de estos, tales como análogos de insulina acilados, y su uso farmacéutico, en particular en el tratamiento o prevención de afecciones médicas relacionadas con la diabetes, la obesidad y enfermedades cardiovasculares.
MX2020001434A 2017-08-17 2018-08-16 Analogos de insulina acilados novedosos y usos de estos. MX2020001434A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17186612 2017-08-17
EP17204872 2017-12-01
PCT/EP2018/072191 WO2019034726A1 (en) 2017-08-17 2018-08-16 NOVEL ACYLATED INSULIN ANALOGUES AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2020001434A true MX2020001434A (es) 2020-03-20

Family

ID=63165388

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001434A MX2020001434A (es) 2017-08-17 2018-08-16 Analogos de insulina acilados novedosos y usos de estos.

Country Status (19)

Country Link
US (2) US10919949B2 (es)
EP (1) EP3668892A1 (es)
JP (2) JP2020531451A (es)
KR (1) KR20200038502A (es)
CN (1) CN111032685A (es)
AU (1) AU2018317810A1 (es)
BR (1) BR112020002364A2 (es)
CA (1) CA3071686A1 (es)
CL (1) CL2020000310A1 (es)
CO (1) CO2020002500A2 (es)
IL (1) IL272394A (es)
MA (1) MA49896A (es)
MX (1) MX2020001434A (es)
PE (1) PE20211264A1 (es)
PH (1) PH12020550050A1 (es)
RU (1) RU2020108281A (es)
SG (1) SG11202001077UA (es)
TW (1) TW201917134A (es)
WO (1) WO2019034726A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
MX2023008330A (es) 2021-01-20 2024-01-18 Viking Therapeutics Inc Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343898A (en) 1980-02-11 1982-08-10 Novo Industri A/S Process for preparing esters of human insulin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5616729A (en) 1986-07-17 1997-04-01 Board Of Governors Of Wayne State University Enhanced chemiluminescence from 1,2-dioxetanes through energy transfer to tethered fluorescers
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
DK33591D0 (es) 1991-02-27 1991-02-27 Novo Nordisk As
IL114160A (en) 1994-06-17 2006-12-31 Novo Nordisk As Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
DE69735242T2 (de) 1996-12-20 2006-09-21 Novo Nordisk A/S N-terminal verlängerte proteine exprimiert in hefe
AU2624400A (en) 1999-01-26 2000-08-07 Eli Lilly And Company Monodisperse hexameric acylated insulin analog formulations
JP2003518917A (ja) * 1999-05-19 2003-06-17 ゼンコー 糖尿病の処置に有用なインシュリン様活性を有する新規タンパク質
RU2283846C2 (ru) 1999-12-29 2006-09-20 Ново Нордиск А/С Предшественник инсулина, способ его получения и применение
EP1692168B1 (en) 2003-12-03 2011-07-20 Novo Nordisk A/S Single-chain insulin
WO2006008238A1 (en) * 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
JP4933455B2 (ja) 2005-02-02 2012-05-16 ノヴォ ノルディスク アー／エス 新規のインスリン誘導体
EP1991576B1 (en) * 2006-02-27 2010-09-29 Novo Nordisk A/S Insulin derivatives
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
AU2008288413B2 (en) 2007-08-15 2013-09-26 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
RU2571857C2 (ru) 2008-03-18 2015-12-20 Ново Нордиск А/С Стабилизированные по отношению к протеазам ацилированные аналоги инсулина
WO2010080609A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
US20110245164A1 (en) 2008-12-19 2011-10-06 Indiana University Research And Technology Corporation Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor
JP2012532177A (ja) 2009-07-06 2012-12-13 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 熱及び振動安定性インスリン製剤
WO2011159882A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Novel stabilized insulin agonists
WO2011159895A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
JP5973427B2 (ja) 2010-06-23 2016-08-23 ノヴォ ノルディスク アー／エス 追加のジスルフィド結合を含有するインスリン類似体
EP2585102B1 (en) 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Amide-based insulin prodrugs
WO2011163460A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor
WO2012015692A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
WO2012049307A2 (en) 2010-10-15 2012-04-19 Novo Nordisk A/S Novel n-terminally modified insulin derivatives
AR087433A1 (es) 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
EP2793932B1 (en) 2011-12-20 2018-10-03 Indiana University Research and Technology Corporation Ctp-based insulin analogs for treatment of diabetes
WO2013093009A1 (en) 2011-12-21 2013-06-27 Novo Nordisk A/S N -terminally modified insulin derivatives
JP6387008B2 (ja) 2012-09-26 2018-09-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリンアナローグダイマー
EP2925345B1 (en) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
US10421795B2 (en) 2012-12-17 2019-09-24 Merck Sharp & Dohme Corp. Process for purifying insulin and analogues thereof
US20160024169A1 (en) 2013-03-14 2016-01-28 Indiana University Research And Technology Corporation Insulin-incretin conjugates
US20160193154A1 (en) 2013-07-24 2016-07-07 Novo Nordisk A/S Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and an Anionic Copolymer Coating
MX366852B (es) 2013-10-04 2019-07-25 Merck Sharp & Dohme Conjugados de insulina sensibles a glucosa.
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
CA2966765C (en) 2014-11-21 2020-04-14 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
EP3250225A1 (en) 2015-01-29 2017-12-06 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating
WO2016144658A1 (en) 2015-03-10 2016-09-15 Merck Sharp & Dohme Corp. Process for preparing recombinant insulin using microfiltration
US20180110863A1 (en) 2015-04-08 2018-04-26 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
WO2016172269A2 (en) 2015-04-20 2016-10-27 University Of Utah Research Foundation Insulin analogs having shortened b chain peptides and associated methods
WO2017032798A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
EP3341402A1 (en) * 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
US20190010206A1 (en) * 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
WO2017040363A1 (en) 2015-09-02 2017-03-09 Merck Sharp & Dohme Corp. A process for obtaining insulin with correctly formed disulfide bonds

Also Published As

Publication number Publication date
TW201917134A (zh) 2019-05-01
US20210094999A1 (en) 2021-04-01
JP2022105082A (ja) 2022-07-12
MA49896A (fr) 2020-06-24
BR112020002364A2 (pt) 2020-09-01
CL2020000310A1 (es) 2020-07-10
JP2020531451A (ja) 2020-11-05
RU2020108281A (ru) 2021-08-26
SG11202001077UA (en) 2020-03-30
CO2020002500A2 (es) 2020-06-09
KR20200038502A (ko) 2020-04-13
PH12020550050A1 (en) 2020-10-19
PE20211264A1 (es) 2021-07-15
RU2020108281A3 (es) 2022-03-09
IL272394A (en) 2020-03-31
EP3668892A1 (en) 2020-06-24
US10919949B2 (en) 2021-02-16
WO2019034726A1 (en) 2019-02-21
CA3071686A1 (en) 2019-02-21
CN111032685A (zh) 2020-04-17
US20190194285A1 (en) 2019-06-27
AU2018317810A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
PH12017501674A1 (en) Amylin analogues
SA519401239B1 (ar) نظائر أميلين
PH12016501724A1 (en) Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
MA49339A (fr) Conjugués insuline-fc à extension oligomère
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
PH12019502655A1 (en) Acylated insulin compound
PH12019501363A1 (en) Insulin containing pharmaceutical compositions
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
MX2016013029A (es) Compuestos de indanona sustituidos como modulares de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
MX2023000398A (es) Analogos de insulina novedosos y usos de estos.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
MX2019003725A (es) Glicinato de metformina, composiciones farmaceuticas que comprenden la misma, y metodos de uso de la misma.
MX2019002647A (es) Composiciones de tesofensina.
WO2020018058A3 (en) The injectable micronized human insulin
EA201400536A1 (ru) Способы получения двойных солей лоркасерина (варианты), продукты способов, двойные соли, фармацевтические композиции для лечения и/или профилактики нарушений, связанных с ожирением, их применение и способ лечения и/или профилактики нарушений, связанных с ожирением
MX2018000418A (es) Derivados de amida que tienen actividad multimodal contra el dolor.
MX2017006278A (es) Homodimero terapeutico y usos del mismo.
LV15072A (lv) Farmaceitiska kompozīcija izmantošanai patoloģiska stāvokļa, kam raksturīga paaugstināta iNOS gēna ekspresija, profilaksei un ārstēšanai